Marshall Wace’s Mustang Bio MBIO Stock Holding History

Marshall Wace’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-57	Closed	-$70K	–	3731
2021 Q4	$70K	Buy	+57	New	+$92K	﹤0.01%	3480
2020 Q4	–	Sell	-28	Closed	-$66K	–	2061
2020 Q3	$66K	Buy	+28	New	+$69K	﹤0.01%	1526

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's MBIO Position: Q1 2022 in Review

Marshall Wace sold out of Mustang Bio (MBIO) in Q1 2022, closing a stake of 57 shares — an estimated $70K sold.

Marshall Wace first reported a position in MBIO in Q3 2020 and held it in 2 quarters. The position peaked at $70K in Q4 2021. 81 funds tracked by Wall St. Rank hold MBIO as of Q1 2022.

Marshall Wace reported no remaining Mustang Bio position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 57 Mustang Bio shares in Q1 2022, an estimated $70K.
Marshall Wace first reported a position in Mustang Bio in Q3 2020 and held it in 2 quarters.
Marshall Wace's Mustang Bio position peaked at $70K in Q4 2021.
81 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.